Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Liraglutide has been previously shown to increase bone formation and prevent bone loss in obese women who have lost weight. For this new study, 195 obese participants shed at least 5% of their ...

Patients with alcohol use disorder who used GLP-1 agonists to treat obesity or type 2 diabetes had a decreased risk for hospitalization due to alcohol use disorder, according to a study published ...

Liraglutide was shown to rapidly improve insulin sensitivity as well as decrease blood glucose within two weeks of beginning treatment and before any weight loss. "GLP-1R agonists are an exciting ...

The lowest risks for AUD and substance use disorder (SUD) hospitalization were seen in association with semaglutide use (adjusted hazard ratios, 0.64 and 0.68 for AUD and any SUD, respectively ...

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies ...

Victoza is a once-daily subcutaneous injection used to treat type 2 diabetes for patients 10 years or older, and its compound patent expired in 2023. Teva filed its application back in February 2017.

Subsequent hospitalization rates were lower among patients with type 2 diabetes who received liraglutide compared with glimepiride.

Combining liraglutide with a very low-calorie ketogenic diet can lead to greater weight loss than the diet alone in adults ...

Ozempic (semaglutide), Victoza (liraglutide), and Wegovy (semaglutide) are popular medications used to treat Type 2 diabetes or help with weight loss. They belong to a class called glucagon-like ...